Pfizer Limited Announces FY 2026 Results, Recommends 750% Dividend
Pfizer Limited announced the outcome of its Board Meeting held on May 12, 2026, releasing the audited financial results for the fiscal year ended March 31, 2026.The Board of Directors recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each, representing a 750% payout ratio, for the financial year ended March 31, 2026. This dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting. The recommended dividend would be paid on or after August 4, 2026, to shareholders whose names appear in the Register of Members as of the record date, scheduled for Friday, July 17, 2026.
The Company will convene its 75th Annual General Meeting (AGM) on Tuesday, July 28, 2026, via Video-Conferencing/Other Audio-Visual Means.
Financial Performance Highlights
The audited financial results and statement of assets and liabilities for the year ended March 31, 2026, were submitted. The financial reports were audited by M/s. B S R & Co., LLP, which issued an audit report with an unmodified opinion.Key figures for the financial year ended March 31, 2026 (Amounts in ₹ lakh):
| Metric | Current Year (Ended Mar 31, 2026) | Previous Year (Ended Mar 31, 2025) |
|---|---|---|
| Total Income | 2,707.60 | 2,453.60 |
| Total Expenses | 1,682.77 | 1,610.32 |
| Net Profit for the Year | 722.43 | 767.60 |
| Total Comprehensive Income | 726.27 | 768.34 |
| Earnings per Share (Basic and Diluted) | 157.92 | 167.79 |
According to the audited cash flow statements for the year ended March 31, 2026:
| Activity | Amount (₹ lakh) |
|---|---|
| Net Cash generated from Operating Activities (A) | 967.57 |
| Net cash (used) in Investing Activities (B) | (561.67) |
| Net cash (used) in Financing Activities (C) | (798.31) |
| Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C) | (392.41) |
As of March 31, 2026, the total assets of Pfizer Limited stood at ₹4,921.88 lakh, compared to ₹4,911.11 lakh recorded on March 31, 2025.
Balance Sheet Summary (₹ lakh):
| Category | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Total Non-Current Assets | 1,118.66 | 1,398.26 |
| Total Current Assets | 3,803.22 | 3,512.85 |
| Total Assets | 4,921.88 | 4,911.11 |
| Total Equity | 4,202.90 | 4,217.41 |
| Total Liabilities | 718.98 | 693.70 |
| Total Equity and Liabilities | 4,921.88 | 4,911.11 |
Corporate Governance and Appointments
At the Board meeting, the Company also appointed M/s. Kishore Bhatia & Associates (Firm Registration No. 000294) as the Cost Auditors for the financial year ending March 31, 2027.The Company confirmed that it does not fall under the category of a Large Corporate as of March 31, 2026. This assessment was based on the fact that the Company had no outstanding long-term borrowings exceeding ₹1,000 Crores.
PFIZER Stock Price Movement
Pfizer Limited shares today slipped by 3.08% to close at ₹4725.9, marking a decline of ₹150.40 for the session. The stock experienced a significant trading day, moving on a total traded volume of 23,483 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.